WuXi XDC Cayman Inc.

Company Profile

Sector

Healthcare

Industry

Diagnostics & Research

Employees

2,662

Website

wuxixdc.com

Country

China

Exchange

HKSE

Founded 2013Wuxi, ChinaSubsidiary of WuXi Biologics (Cayman) Inc

WuXi XDC Cayman Inc., an investment holding company is a contract research, development, and manufacturing organization globally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates international sales contracting services.

Additionally, it engages in the R&D, manufacturing, and marketing of anti-tumor drugs. WuXi XDC Cayman Inc. has a strategic collaboration with Earendil Labs; and Akari Therapeutics.

Founded in 2013, the company is headquartered in Wuxi, China. WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.

Key Stats

52-Week Range

HK$43.50HK$85.50

Beta-0.78

Trailing P/E41.92

Forward P/E21.86

Trailing EPS1.30

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceHK$82.67

RecommendationStrong Buy

Recommendation Mean1.25

Recent SEC Filings

SEC filings for this ticker are not available yet.